Gubra A/S
Research Gubra A/S (GUBRA) on Bullrun: market cap DKK 6.38B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGUBRA
- ExchangeCO
- CountryDenmark
- SectorHealthcare
- IndustryBiotechnology
- CurrencyDKK
- Market capDKK 6.38B
- Financial periodFY2025
- RevenueDKK 2.64B
- Revenue growth892.2%
- Net incomeDKK 1.69B
- Free cash flowDKK 1.69B
- Gross margin97.0%
Valuation Snapshot
latest market cap is DKK 6.38B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | DKK 2.64B | DKK 1.69B | DKK 1.69B | 97.0% | 102.7 | DKK 32.19M | DKK 107.44M | DKK 1.15B |
| FY2024 | DKK 265.74M | -DKK 36.50M | -DKK 27.10M | 61.9% | -2.2 | DKK 134.40M | DKK 96.45M | DKK 450.57M |
| FY2023 | DKK 205.01M | -DKK 44.52M | -DKK 60.62M | 56.1% | -2.9 | DKK 53.40M | DKK 71.44M | DKK 479.66M |
| FY2022 | DKK 199.38M | DKK 4.31M | DKK 10.19M | 49.0% | 0.26 | DKK 71.93M | DKK 69.40M | DKK 108.21M |
| FY2021 | n/a | n/a | n/a | n/a | 4.16 | DKK 115.79M | n/a | DKK 151.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | DKK 6.38B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 DKK.
| Year | Dividends/share |
|---|---|
| FY2025 | 61.2 DKK |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gubra A/S's market cap?
Gubra A/S's market capitalization is DKK 6.38B.
What does Gubra A/S do?
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green.